Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Mahmoudian, J; Ghods, R; Jeddi-Tehrani, M; Ghaffari-Tabrizi-Wizsy, N; Nejadmoghaddam, MR; Ghahremanzadeh, R; Ostad, SN; Zarnani, AH.
Therapeutic Potential of an Anti-PLAC1 Antibody Drug Conjugate in a Murine Model of Human Breast Cancer
IRAN J IMMUNOL. 2025; 22(3): 192-206.
Doi: 10.22034/iji.2025.106670.3019
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Ghaffari Tabrizi-Wizsy Nassim
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Background: Placenta-specific 1 (PLAC1) is an oncoplacental genes aberrantly expressed in various malignancies. Antibody-drug conjugates (ADC) offer a promising therapeutic approach by enhancing efficacy and reducing toxicity of treatment compared to cytotoxic small-molecule agents. Objective: To evaluate the efficacy of an SN38-conjugated monoclonal anti-PLAC1 antibody in a mouse model of breast cancer. Methods: Anti-human PLAC1 monoclonal antibodies were generated and characterized. SN38 was conjugated to an anti-PLAC1 antibody (clone: 2H12C12) and conjugation efficacy was determined by UV spectrophotometry. The antigen-binding activity of the conjugated antibody was assessed using ELISA and flow cytometry. In vitro, the cytotoxic profile of 2H12C12-SN38 was evaluated in MDA-MB-231 breast cancer cells using a fluoroimetric viability assay. The impact of 2H12C12-SN38 on MDA-MB-231 tumor growth and angiogenesis ex vivo was examined using chorioallantoic membrane (CAM) assay followed by immunohistochemical analysis. Pharmacokinetics of 2H12C12-SN38 in mice was determined by serial venipuncture following ADC administration. The inhibitory effects of anti-PLAC1 ADC on tumor growth were evaluated in a nude mouse xenograft model of human breast cancer. Results: The anti-PLAC1 ADC exhibited a substantial cytotoxicity against MDA-MB-231 cells, with effects observed at concentration as low as similar to 33 nM. In the CAM assay, the ADC significantly reduced the growth of MDA-MB-231 tumor but did not produce a significant effect on tumor angiogenesis. Pharmacokinetic analysis in mice demonstrated an average half-life (t1/2) of approximately 80 hours. In a nude mouse xenograft model, treatment with the ADC resulted in a significant reduction in tumor size compared with isotype-matched antibody-SN38 conjugate, or free SN38. Conclusion: This study represents the first therapeutic application of anti-PLAC1 ADC in a xenograft model of human breast cancer. Our findings support the embryonic origin of cancers and highlight the potential therapeutic value of targeting oncofetal antigens in human breast cancer.
- Find related publications in this database (Keywords)
- Placenta-specific 1 (PLAC1)
- SN38
- Chorioallantoic membrane
- Tumorigenesis
- Breast cancer